Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer

NCT04584255 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04584255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04584255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 21, 2021
Completion date
July 17, 2029
Enrollment
66 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, deleterious palb2 gene mutation, germline brca1 gene mutation, germline brca2 gene mutation, her2-negative breast cancer, stage i breast cancer, stage ii breast cancer, stage iii breast cancer